 This study examined the effectiveness of n-acetylcysteine, NAC, as an antioxidant in reducing inflammatory markers in end-stage renal disease, ESRD, patients undergoing hemodialysis. The study found that NAC significantly decreased levels of hematocrit, ferritin, and high sensitivity C-reactive protein, HSCRP, indicating its potential use in treating inflammation in ESRD patients. Additionally, NAC did not reduce levels of calcium, which may be due to the short duration of the study. Overall, this study suggests that NAC could be used as an adjunctive therapy to treat inflammation in ESRD patients. This article was authored by Bauman-Bascherdascht, Roy Alley, Sosan-Mohammadi K-Bar, and others.